Cutaneous toxicities in melanoma patients receiving checkpoint inhibitor therapy, a retrospective review: The experience of a single large specialist institution.
CPI was approved by the European Medicines Agency (EMA) in 2012 for advanced melanoma and extended to include adjuvant melanoma treatment in 2018. Expectation for survival in advanced melanoma now exceeds 50% at 5 years with first-line combination ipilimumab and nivolumab. Cutaneous irAEs occur in up to 50% receiving ipilimumab and 40% receiving anti-programmed cell death 1 inhibitors. The majority of cutaneous toxicities are mild, however severe reactions are reported.